Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Juan Manuel Ramos-Goñi

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|October 15, 2013
Cost-utility of ranolazine for the symptomatic treatment of patients with chronic angina pectoris in SpainAlvaro Hidalgo-Vega, Juan Manuel Ramos-Goñi, Renata Villoro
Gaceta Sanitaria|December 18, 2018
Application of two-part models and Cholesky decomposition to incorporate covariate-adjusted utilities in probabilistic cost-effectiveness modelsArantzazu Arrospide, Juan Manuel Ramos-Goñi, Petros Pechlivanoglou, et al.
Plos One|August 7, 2025
Health-related quality of life and QALY loss under COVID-19 lockdown: The case of SpainMathieu F Janssen, Kim Rand, Anabel Estévez-Carrillo, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 18, 2017
Less Is More: Cross-Validation Testing of Simplified Nonlinear Regression Model Specifications for EQ-5D-5L Health State ValuesKim Rand-Hendriksen, Juan Manuel Ramos-Goñi, Liv Ariane Augestad, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|June 8, 2020
An exploration of methods for obtaining 0 = dead anchors for latent scale EQ-5D-Y valuesKoonal K Shah, Juan Manuel Ramos-Goñi, Simone Kreimeier, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 22, 2019
Overview, Update, and Lessons Learned From the International EQ-5D-5L Valuation Work: Version 2 of the EQ-5D-5L Valuation ProtocolElly Stolk, Kristina Ludwig, Kim Rand, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|June 30, 2018
The EQ-5D-5L Valuation study in ThailandJuntana Pattanaphesaj, Montarat Thavorncharoensap, Juan Manuel Ramos-Goñi, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 17, 2015
Learning and satisficing: an analysis of sequence effects in health valuationBenjamin M Craig, Shannon K Runge, Kim Rand-Hendriksen, et al.
Dermatology and Therapy|October 28, 2023
Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab versus Dupilumab in Moderate-to-Severe Atopic DermatitisKim Rand, Juan Manuel Ramos-Goñi, Bülent Akmaz, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|March 18, 2021
Valuing EQ-5D-Y-3L Health States Using a Discrete Choice Experiment: Do Adult and Adolescent Preferences Differ?David J Mott, Koonal K Shah, Juan Manuel Ramos-Goñi, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|October 15, 2013
Cost-utility of ranolazine for the symptomatic treatment of patients with chronic angina pectoris in SpainAlvaro Hidalgo-Vega, Juan Manuel Ramos-Goñi, Renata Villoro
Gaceta Sanitaria|December 18, 2018
Application of two-part models and Cholesky decomposition to incorporate covariate-adjusted utilities in probabilistic cost-effectiveness modelsArantzazu Arrospide, Juan Manuel Ramos-Goñi, Petros Pechlivanoglou, et al.
Plos One|August 7, 2025
Health-related quality of life and QALY loss under COVID-19 lockdown: The case of SpainMathieu F Janssen, Kim Rand, Anabel Estévez-Carrillo, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 18, 2017
Less Is More: Cross-Validation Testing of Simplified Nonlinear Regression Model Specifications for EQ-5D-5L Health State ValuesKim Rand-Hendriksen, Juan Manuel Ramos-Goñi, Liv Ariane Augestad, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|June 8, 2020
An exploration of methods for obtaining 0 = dead anchors for latent scale EQ-5D-Y valuesKoonal K Shah, Juan Manuel Ramos-Goñi, Simone Kreimeier, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 22, 2019
Overview, Update, and Lessons Learned From the International EQ-5D-5L Valuation Work: Version 2 of the EQ-5D-5L Valuation ProtocolElly Stolk, Kristina Ludwig, Kim Rand, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|June 30, 2018
The EQ-5D-5L Valuation study in ThailandJuntana Pattanaphesaj, Montarat Thavorncharoensap, Juan Manuel Ramos-Goñi, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 17, 2015
Learning and satisficing: an analysis of sequence effects in health valuationBenjamin M Craig, Shannon K Runge, Kim Rand-Hendriksen, et al.
Dermatology and Therapy|October 28, 2023
Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab versus Dupilumab in Moderate-to-Severe Atopic DermatitisKim Rand, Juan Manuel Ramos-Goñi, Bülent Akmaz, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|March 18, 2021
Valuing EQ-5D-Y-3L Health States Using a Discrete Choice Experiment: Do Adult and Adolescent Preferences Differ?David J Mott, Koonal K Shah, Juan Manuel Ramos-Goñi, et al.
Pageof 2